← All organizations
Highest phase reached
Phase 2
First clinical trial
Apr 1, 2005Last known activity
Oct 10, 2024
Timeline
1940s
- Jan 1, 1946
Damon Runyon Cancer Research Foundation— Founded
Drugs by trial phase (9 distinct, 5 trials)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Anemia, Refractory
- Anemia, Refractory, with Excess of Blasts
- Burkitt Lymphoma
- Dyssomnias
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Prolymphocytic
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphomatoid Granulomatosis
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Parasomnias
- Plasmablastic Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Sleep Initiation and Maintenance Disorders
- Sleep Wake Disorders
- Syndrome
Recent trials (5)
- NCT06240754CollaboratorPhase 2Oct 10, 2024
- NCT01921296CollaboratorPhase 2Aug 1, 2013
- NCT01112514CollaboratorN/AFeb 1, 2010
- NCT00343798CollaboratorPhase 1Apr 1, 2006
- NCT00185731CollaboratorPhase 2Apr 1, 2005
Details
- Founded
- New York City, NY, US Jan 1, 1946
- Last known activity
- Oct 10, 2024